Related Experiment Video

Updated: Jan 18, 2026

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.7K

Cytochrome P450 Eicosanoid Signaling Pathway in Colorectal Tumorigenesis

Weicang Wang1, Katherine Z Sanidad2, Guodong Zhang3,4

  • 1Department of Food Science, University of Massachusetts, Amherst, MA, USA.

Advances in Experimental Medicine and Biology
|September 29, 2019
PubMed

Insights

Discovering new targets for colorectal cancer (CRC) is vital. The cytochrome P450/soluble epoxide hydrolase (CYP/sEH) pathway and its metabolites are key players in colon inflammation and CRC development.

Area of Science:

  • Biomedical Science
  • Oncology
  • Molecular Biology

Background:

  • Colorectal cancer (CRC) is a leading cause of cancer death in the US.
  • Novel therapeutic targets are needed to combat CRC.
  • The cytochrome P450 (CYP)/soluble epoxide hydrolase (sEH) pathway is implicated in inflammation and cancer.

Purpose of the Study:

  • To review recent studies on the role of the CYP/sEH eicosanoid pathway in CRC pathogenesis.
  • To highlight the potential of this pathway as a therapeutic target for CRC.

Main Methods:

  • Literature review of recent studies.
  • Analysis of the role of CYP/sEH pathway metabolites in colonic inflammation and CRC.

Main Results:

  • The CYP/sEH pathway and its eicosanoid metabolites are critical in colonic inflammation.
  • These pathways play significant roles in the development of CRC.
  • Evidence suggests therapeutic potential for targeting the CYP/sEH pathway in CRC.

Conclusions:

  • The CYP/sEH eicosanoid pathway is a promising area for CRC research.
  • Targeting this pathway could lead to new strategies for CRC prevention and treatment.
Keywords:
Colonic inflammationColorectal cancerCytochrome P450EicosanoidsSoluble epoxide hydrolase

More Related Videos

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.4K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.6K

Related Concept Videos

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.8K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.5K